Clinical Analysis of Renoprotective Responding Patients Administrated with Oral Adsorbent in Chronic Renal Failure Secondary to Chronic Glomerulonephritis
Clinical Analysis of Renoprotective Responding Patients Administrated with Oral Adsorbent in Chronic Renal Failure Secondary to Chronic Glomerulonephritis
复制标题
口服吸附剂治疗慢性肾小球肾炎继发慢性肾功能衰竭肾保护反应患者的临床分析
DOI：
10.1046/j.1526-0968.2003.00024.x
复制
发表时间：
2003
影响因子：
1.9
通讯作者：
S. Koshikawa
中科院分区：
文献类型：
--
作者：
T. Sanaka;T. Akizawa;K. Koide;S. Koshikawa
翻译后摘要：口服吸附剂（AST-120），去除尿毒症毒素已经减弱了肾功能不全的进展。 尽管在给药期间观察到血清肌酐（Scr）水平降低，但预计口服吸附剂的作用因患者而异。在本研究中，澄清了背景的差异。方法：共842例患者的Scr从3.8上升到4.8 mg/dL，在过去的5.2个月进行了调查。 在6个月的给药期间，抗高血压药物和膳食蛋白质摄入量未发生变化。 根据Scr水平的变化将患者分为3个疗效组; Scr下降的患者被分为A组（N = 290），增加<1.5倍的患者被定义为B组（N = 428），增加≥ 1.5倍的患者被定义为C组（N = 124）。 结果：用药前，三组血肌酐水平无明显差异。A组无患者接受透析，而B组和C组分别有12%和40%的患者需要透析。A组1/Scr随时间的斜率、血清尿素氮、尿酸、磷酸盐、总蛋白和舒张压均有所改善。B组有中度改善，C组改善较少。结论：在本研究中，相当多的患者（占人群的29%）被认为是报告重度慢性肾衰竭可逆性的首例病例。除低蛋白血症、高胆固醇血症、贫血或高血压患者外，AST-120可减弱或阻止重度慢性肾小球肾炎患者的进展。
Abstract: An oral adsorbent (AST‐120) that removes uremic toxin has attenuated the progression of renal dysfunction. Although there were decreased serum creatinine (Scr) levels observed during administration, it is expected that the action of an oral adsorbent is different according to the patient. In the present study, the difference in the background was clarified. Methods: A total of 842 patients whose Scr had increased from 3.8 to 4.8 mg/dL during the prior 5.2 months were investigated. Antihypertensive medications and dietary protein intake were unmodified during 6 months administration. The patients were divided into three efficacy groups based on the changes in Scr level; those who had a decrease in Scr were grouped as Group A (N = 290), while those with a <1.5‐fold increase were defined as Group B (N = 428) and those with a ≥1.5‐fold increase were defined as Group C (N = 124). Results: Before administration, these three groups were indistinguishable by the Scr level. No Group A patient went onto dialysis, whereas 12% and 40% of Group B and C patients, respectively, required dialysis. In Group A, the slopes of 1/Scr over time, serum urea nitrogen, uric acid, phosphate, total protein, and diastolic blood pressure were all improved. Group B improved moderately and Group C showed less improvement. Conclusions: In this study, a fairly large number of patients (29% of the population) were believed to be the first case to report the reversibility of severe chronic renal failure. Except in patients with hypoproteinemia, hypercholesterolemia, anemia or hypertension, AST‐120 either attenuates or arrests the progression in patients with severe chronic glomerulonephritis.
肾脏疾病中药物和内源性配体的结合受损。
DOI：
10.1016/s0272-6386(83)80038-9
发表时间：
1983
期刊：
American journal of kidney diseases : the official journal of the National Kidney Foundation
影响因子：
--
作者：
Gulyassy,PF;Depner,TA
通讯作者：
Depner,TA
尿毒症中蛋白质结合抑制剂抑制离体灌注肾中对氨基马尿酸的转运。
DOI：
10.1016/s0272-6386(84)80046-3
发表时间：
1984
期刊：
American journal of kidney diseases : the official journal of the National Kidney Foundation
影响因子：
--
作者：
Depner,TA;Sanaka,T;Stanfel,LA
通讯作者：
Stanfel,LA